Global Stem Cell Therapy Market By Cell Source (Ipscs, Ppscs, Neural), By Type (Allogenic And Autologous), By Application (Cardiovascular, Diabetes), By End User (Hospitals & Clinics, Academic & Research Centers) By Region And Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, And Forecast; 2023-2032

Report Overview

The Global Stem Cell Therapy Market Size was valued at USD 11.1 billion in 2022 and will expand to USD 44.5 billion in 2032 with a CAGR of 15.3% in the forecast period 2023-2032.

Stem cell therapy is used for stem cell transplants in which stem cells are replaced by chemotherapy or act as a donor’s immune system to fight diseases related to blood or cancer, such as multiple myeloma, lymphoma, neuroblastoma, and leukemia. Cell therapy includes types like mesenchymal stem cells (MSCs), skin stem cells (SSCs), hematopoietic stem cells (HSCs), and neural stem cells (NSCs). The cost of stem cell therapy procedures can cost between USD 5,000 and USD 50,000.

The market for stem cell therapy can be increased by boosting funding to stem cell research, increasing clinical trials linked to stem cell therapy, and boosting the number of production facilities for cell therapy. During the pandemic, many cell therapies clinical trials have been done due to the advantages of stem cell therapies.

*Actual Numbers Might Vary In The Final Report

Key Takeaways

• The worldwide stem cell therapy market size was USD 11.1 billion in 2022.
• This market is expected to reach USD 44.5 billion by 2032.
• The stem cell therapy market is growing at a CAGR of 15.3%.
• The cost of stem cell therapy can range from USD 5,000 to USD 50,000.
• Allogenic therapy had a 74% market share in 2022.
• Hospitals and clinics were the largest end-users, with a 28% market share.
• North America dominated the market with a 35% revenue share in 2022.
• Europe held a 29% revenue share in 2022.
• Investments in stem cell research and clinical trials have boosted the market.
• Increasing awareness of stem cell therapy’s importance is driving growth.
• Stem cell banking is on the rise due to public awareness.
• The global cancer burden is increasing, driving the need for stem cell transplants.
• Ethical issues and regulatory concerns can limit the growth of stem cell research.

By Cell Source Analysis

The Dipose Tissue Segment Segment Accounted for The Largest Market Share In Cell Source Type Owing To its Used In Adipose Tissue Or Fatty Tissue As A Specialized Connective Tissue

Based on cell source types, the global stem cell therapy market share is segmented into IPSCs, PPSCs, neural, embryo/cord, adipose tissue, and bone marrow. Among these cell sources, the largest market share was occupied by the adipose tissue segment with a 34% market share in 2022.

Because these cell source segments are used in adipose tissue or fatty tissue is a specialized connective tissue consisting of lipid-rich cells called adipocytes found mainly under the skin and also in deposits between the muscles, around the heart, in the intestines, membrane folds of the intestine, and elsewhere.

By Type Analysis

The Allogenic Segment Accounted for the Largest Market Share In The Type Owing To Their Prevalence Of Cancer And Related Diseases Among Individuals

Based on the type, the global stem cell therapy market share is segregated into allogenic stem cell therapy and autologous stem cell therapy. Among these types, the largest market share was occupied by the allogenic segment with a 74% market share in 2022. Because global consumption of allogeneic stem grafts is growing owing to the increasing incidence of cancer and other related disorders.

According to the WHO, children between the ages of 0 to 19 are diagnosed with almost 300K new cases of cancer annually. In 2022, there will be 21 million new cases of cancer, according to estimates. This puts a strain on the global healthcare system and increases the demand for cancer treatments that are efficient anywhere in the world.

By Application Type Analysis

The Diabetes Segment Accounted for The Largest Market Share In The Application Type Owing To The Large Number Of Individual

Based on application type, the global stem cell therapy market is segmented into cardiovascular, diabetes, cancer, musculoskeletal disorders, and gastrointestinal diseases. Among these types, the largest market share was occupied by the diabetes segment with a 28% market share in 2022.

Because the WHO estimates that 450 million people worldwide have diabetes. Diabetes is more common in nations with low and medium incomes. Diabetes, also referred to as diabetes mellitus, is just a metabolic disorder that develops whenever blood glucose levels are too high. Over time, this illness causes major harm to the kidneys, eyes, blood vessels, heart, and eyes.

By End User Type Analysis

The Hospitals & Clinics Segment Accounted for The Largest Market Share In The End User Type Owing To Its Increased Frequency Of Skin Conditions Like Acne

Based on end-user type, the global stem cell therapy market is segmented into hospitals & clinics, academic & research centers, ambulatory surgical centers, and other end users. Among these types, the largest market share was occupied by the hospitals & clinics segment with a 28% market share in 2022 because, the increasing frequency of skin conditions like acne.

Key Market Segments

By Cell Source

• IPSCS
• PPSCS
• Neural
• Embryo/cord
• Adipose Tissue
• Bone Marrow

By Type

• Allogenic
• Autologous

By Application

• Cardiovascular
• Diabetes
• Cancer
• Musculoskeletal Disorders
• Gastrointestinal Diseases

By End User

• Hospitals & Clinics
• Academic & Research Centers
• Ambulatory Surgical Centers
• Other End Users

Drivers

Increasing Rate of Chronic Diseases

The need for efficient treatment is being caused by the increasing rate of chronic diseases. Along with the ongoing COVID-19 pandemic, chronic diseases like heart disease, cancer, stroke, respiratory illnesses, neurological disorders, and cardiovascular disorders place a significant strain on society.

According to the Centers for Disease Control (CDC), four out of ten adults in 2019 have more than two chronic diseases, and six out of ten adults have chronic diseases. The data shows how diseases are becoming more prevalent and how well they are being managed. Clinical trials are anticipated to increase the demand of stem cells in the forecast period.

Restraints

Expansion of Stem Cell-Based Therapy Is Constrained By Ethical Issues

Even though stem cell research holds immense potential for the medical sector, its expansion is constrained by ethical issues from regulatory body. The destruction of the human embryonic stem cell is one of the main obstacles that might have hindered the advancement of stem cell research.

Opportunity

Demand for Stem Cells Banking Has Increased For Development Activity

The demand for the banking of stem cells has increased as the number of chronic disorders and life-challenging genetic abnormalities have increased. A growing number of firms have entered the stem cell banking sector as a result of rising public awareness of stem cell therapy. Genetically programmed adult stem cells using embryonic stem cell known as pluripotent stem cells to increase sales and market for stem cell therapy.

Regional Analysis

North America Dominated the Global Stem Cell Therapy Market

In 2022, North America held a 35% share of the global stem cell therapy market. The region benefits due to the most recent cutting-edge technologies, economic expansion, and significant governmental & private investment. The availability of the latest research infrastructure increased R&D efforts to create therapeutic choices for chronic diseases, and simple review processes for clinical trials are further market-driving elements in the area.

Major research organizations and market suppliers headquartered here receive significant funding from the United States. The numerous projects in the region’s pipeline are boosting consumer demand.

Asia-Pacific is expanding at the fastest rate & Europe owns the second-largest share

Due to a rise in the demand for stem cell therapy and an increased prevalence of chronic and neurological illnesses, Europe owns the second-largest share of the market.

The cell therapy market growth in Asia-Pacific, it is expanding at the fastest growth rate because of its rapid growth and the arrival of several companies. Additionally, the Asia Pacific region’s growing use of stem cell therapy treatments and rising cancer prevalence are projected to fuel market expansion.

Key Regions

North America

• The US
• Canada
• Mexico

Eastern Europe

• Russia
• Poland
• The Czech Republic
• Greece
• Rest of Eastern Europe

Western Europe

• Germany
• France
• The UK
• Spain
• Italy
• Portugal
• Ireland
• Austria
• Switzerland
• Benelux
• Nordic
• Rest of Western Europe

APAC

• China
• Japan
• South Korea
• India
• Australia & New Zealand
• Indonesia
• Malaysia
• Philippines
• Singapore
• Thailand
• Vietnam
• Rest of APAC

  Latin America

• Brazil
• Colombia
• Chile
• Argentina
• Costa Rica
• Rest of Latin America

Middle East & Africa

• Algeria
• Egypt
• Israel
• Kuwait
• Nigeria
• Saudi Arabia
• South Africa
• Turkey
• United Arab Emirates
• Rest of MEA

Key Players Analysis

To increase their market position, Using Methods Such as Alliances, Mergers and acquisitions, Geographic Coverage, And Strategic Partnerships. For example, Celularity Inc. and GX Acquisition Corp. signed a merger agreement to speed up the development & production of fresh and novel allogeneic cell therapies like CAR T therapies obtained from the genetically engineered natural killer cell therapies and postpartum placenta.

Market Key Players

With the presence of many local and regional players, the market for companion diagnostics is fragmented. Market players are subject to intense competition from prominent players, particularly those with strong brand recognition and high distribution networks. To stay on top of the market, companies have gained various expansion strategies such as partnerships and product launches.

The following are some of the key market players in the global stem cell therapy industry:

• Seraxis, Inc. (Germany)
• Fresenius Medical Care AG & Co. KGaA (Germany)
• Generex Biotechnology (Canada)
• Medipost Co., Ltd (South Korea)
• Pharmicell Co., Ltd (South Korea)
• JCR Pharmaceuticals Co., (Japan)
• Novadip Biosciences(Belgium)
• Anterogen Co., Ltd (South Korea)
• StemCell Technologies Inc. (Canada)
• Sernava Corp (Canada)
• NextCell Pharma AB (US)
• ViaCyte, Inc. (US)
• Vertex Pharmaceuticals (US)
• NuVasive, Inc. (US)
• Novo Nordisk A/S (Denmark)
• Kadimastem (Israel)
• Betalin Therapeutics Ltd (Israel)
• Other Key Players

Recent Developments

• In February 2022, The Chinese patent office granted Cynata Therapies firm, a patent for its unique “MSC” technology or CymerusTM mesenchymal stem cell. The patent was granted to a company by the close of May 2022 and is valid till March 2037.
• In February 2022, A deal with eQcell has been announced by Likarda (LLC) creating cutting-edge delivery technologies. According to the terms of the agreement, the specialized hydrogel encapsulating product for their equine multipotent stromal cells may be licensed globally.
• January 2022, A well-known biotech business, Gamida Cell, has declared that it will begin a FDA filing for the blood cancer drug omidubicel. However, in order to succeed, it needs a little assistance from a strategic partner and a staff reduction.

Report Scope